gdc
PSSGuide_2021
Pancreatic Cancer

Drugs for Pancreatic Cancer

Here are the drugs and financial support services available to patients receiving treatment for Pancreatic Cancer.

Abraxane (paclitaxel protein-bound particles; albumin-bound)

Drug company: Celgene
800-931-8691

Abraxane is a microtubule inhibitor used, in combination with Gemzar, for the treatment of patients with advanced or metastatic pancreatic cancer as first-line treatment.

Celgene Patient Support offers 3 financial assistance programs for patients using Abraxane:

Celgene Commercial Co-pay Program

This program reduces the prescription copay for Abraxane to $0 for qualifying patients who have private or commercial insurance, with a benefit of up to $10,000 provided annually.

Celgene Patient Assistance Program

Patients with no insurance, or not enough insurance to cover their medication, who meet certain financial criteria may receive Abraxane for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Gemzar (gemcitabine)

Drug company: Eli Lilly
866-472-8663

Gemzar is a nucleoside metabolic inhibitor used as first-line treatment of patients with locally advanced (stage II or III nonresectable) or metastatic (stage IV) pancreatic cancer. Gemzar is also used in patients with pancreatic cancer who have previously received treatment with fluorouracil.

Lilly Oncology does not currently offer any direct financial assistance programs for Gemzar.

Lynparza (olaparib)

Drug company: AstraZeneca
844-275-2360

Lynparza is a PARP inhibitor used for the maintenance treatment of patients with metastatic pancreatic cancer and deleterious or suspected deleterious germline BRCA mutation, as detected by an FDA-approved test, in adults whose disease had not progressed after 16 weeks or more of platinum-based chemotherapy in the first-line setting.

AstraZeneca offers 2 financial assistance programs for patients who have been prescribed Lynparza:

Lynparza Co-pay Savings Program

The patient’s out-of-pocket costs may vary, but this program aims for eligible patients to pay $0 per month for Lynparza, with a maximum out-of-pocket savings of $26,000 annually. This program has no income requirements, but eligible patients must have private health insurance that partially covers the medication costs for Lynparza.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year and must be unable to enroll in Medicare limited income subsidy.

Patients with Medicare Part B coverage should call 800-292- 6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Lynparza (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Onivyde (irinotecan liposome injection)

Drug company: Ipsen
866-435-5677

Onivyde is a topoisomerase inhibitor used, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic pancreatic cancer whose disease has progressed after treatment with Gemzar.

Ipsen Cares offers 2 financial assistance programs for patients using Onivyde:

Onivyde Copay Program

Eligible patients with private insurance will pay $0 per order of Onivyde, with a maximum annual benefit of $20,000.

Ipsen Cares Patient Assistance Program

Uninsured patients who meet the income criteria may be eligible to receive Onivyde at no cost.

Tarceva (erlotinib) Tablets

Drug company: Genentech
866-422-2377

Tarceva is a kinase inhibitor used, in combination with Gemzar, for the treatment of patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed and who have not received previous chemotherapy.

Genentech Oncology offers 1 financial assistance program for patients using Tarceva:

Genentech Patient Foundation

This foundation provides Tarceva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Tarceva is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Table. Drugs Prescribed for Pancreatic Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Gemzar (gemcitabine)
  • Drug company
  • Eli Lilly
  • Indication
  • First-line treatment of locally advanced or metastatic pancreatic cancer

    In patients with pancreatic cancer who have received fluorouracil therapy
  • Patient support services
  • (No specific program)
    866-472-8663

    Drug name (generic name)
  • Lynparza (olaparib)
  • Drug company
  • AstraZeneca
  • Indication
  • Maintenance treatment of patients with metastatic pancreatic cancer and deleterious or suspected deleterious germline BRCA mutation, as detected by an FDA-approved test, in adults whose disease had not progressed after 16 weeks or more of platinum-based chemotherapy in the first-line setting
  • Patient support services
  • Lynparza Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    800-292-6363


    Drug name (generic name)
  • Tarceva (erlotinib) Tablets
  • Drug company
  • Genentech
  • Indication
  • Advanced-stage pancreatic cancer that has spread, grown, or cannot be surgically removed, in combination with Gemzar
  • Patient support services
  • Genentech Patient Foundation
    888-941-3331

Share this:

Last modified: April 7, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest